BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 30083883)

  • 1. A lung squamous carcinoma patient with ROS1 rearrangement sensitive to crizotinib.
    Ju L; Han M; Su J; Wu C; Dong Z
    Cancer Chemother Pharmacol; 2018 Sep; 82(3):561-564. PubMed ID: 30083883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer.
    Li Z; Shen L; Ding D; Huang J; Zhang J; Chen Z; Lu S
    J Thorac Oncol; 2018 Jul; 13(7):987-995. PubMed ID: 29704675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.
    Mazières J; Zalcman G; Crinò L; Biondani P; Barlesi F; Filleron T; Dingemans AM; Léna H; Monnet I; Rothschild SI; Cappuzzo F; Besse B; Thiberville L; Rouvière D; Dziadziuszko R; Smit EF; Wolf J; Spirig C; Pecuchet N; Leenders F; Heuckmann JM; Diebold J; Milia JD; Thomas RK; Gautschi O
    J Clin Oncol; 2015 Mar; 33(9):992-9. PubMed ID: 25667280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fatal interstitial lung disease associated with Crizotinib pathologically confirmed by percutaneous lung biopsy in a patient with ROS1-rearranged advanced non-small-cell lung cancer: a case report.
    Wu S; Liu K; Ren F; Zheng D; Pan D
    BMC Pulm Med; 2018 Jul; 18(1):121. PubMed ID: 30029601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib.
    Xu S; Wang W; Xu C; Li X; Ye J; Zhu Y; Ge T
    BMC Cancer; 2019 Aug; 19(1):769. PubMed ID: 31382924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case of ROS1-rearranged lung adenocarcinoma exhibiting pleural effusion caused by crizotinib.
    Tachi H; Nishino K; Nakaizumi T; Kuramoto K; Shimizu K; Yamamoto Y; Kobayashi K; Ichimura H; Sakata A; Nawa T
    Thorac Cancer; 2020 Jul; 11(7):2063-2066. PubMed ID: 32433811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of crizotinib as neoadjuvant therapy for non-small cell lung cancers patient with ROS1 rearrangement: A case report.
    Zhao S; Zhu S; Lei X; Xu D; Shi T; Chen Q; Ren F; Chen G; Huang D; Xu S
    Thorac Cancer; 2021 Oct; 12(20):2815-2818. PubMed ID: 34405544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib.
    Patil T; Smith DE; Bunn PA; Aisner DL; Le AT; Hancock M; Purcell WT; Bowles DW; Camidge DR; Doebele RC
    J Thorac Oncol; 2018 Nov; 13(11):1717-1726. PubMed ID: 29981925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting ROS1 Rearrangements in Non-small Cell Lung Cancer: Crizotinib and Newer Generation Tyrosine Kinase Inhibitors.
    Morris TA; Khoo C; Solomon BJ
    Drugs; 2019 Aug; 79(12):1277-1286. PubMed ID: 31313100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement.
    Zhang L; Jiang T; Zhao C; Li W; Li X; Zhao S; Liu X; Jia Y; Yang H; Ren S; Zhou C
    Oncotarget; 2016 Nov; 7(46):75145-75154. PubMed ID: 27738334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of ROS1 5' deletions in non-small cell lung cancer.
    Capizzi E; Dall'Olio FG; Gruppioni E; Sperandi F; Altimari A; Giunchi F; Fiorentino M; Ardizzoni A
    Lung Cancer; 2019 Sep; 135():88-91. PubMed ID: 31447007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient harboring a novel PIK3CA point mutation after acquired resistance to crizotinib in an adenocarcinoma with ROS1 rearrangement: A case report and literature review.
    Xu CW; Wang WX; Huang RF; He C; Liao XH; Zhu YC; Du KQ; Zhuang W; Chen YP; Chen G; Fang MY
    Thorac Cancer; 2017 Nov; 8(6):714-719. PubMed ID: 28845578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non-small-cell Lung Cancer Progressing on Crizotinib.
    De Giglio A; Lamberti G; Facchinetti F; Genova C; Andrini E; Dal Bello MG; Tiseo M; Metro G; Chiari R; Ricciuti B
    Clin Lung Cancer; 2020 Sep; 21(5):e478-e487. PubMed ID: 32409267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer.
    Song A; Kim TM; Kim DW; Kim S; Keam B; Lee SH; Heo DS
    Clin Cancer Res; 2015 May; 21(10):2379-87. PubMed ID: 25688157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical activity of brigatinib in ROS1-rearranged non-small cell lung cancer.
    Dudnik E; Agbarya A; Grinberg R; Cyjon A; Bar J; Moskovitz M; Peled N;
    Clin Transl Oncol; 2020 Dec; 22(12):2303-2311. PubMed ID: 32462394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib.
    Bos M; Gardizi M; Schildhaus HU; Heukamp LC; Geist T; Kaminsky B; Zander T; Nogova L; Scheffler M; Dietlein M; Kobe C; Holstein A; Maintz D; Büttner R; Wolf J
    Lung Cancer; 2013 Jul; 81(1):142-3. PubMed ID: 23558310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer.
    Pailler E; Auger N; Lindsay CR; Vielh P; Islas-Morris-Hernandez A; Borget I; Ngo-Camus M; Planchard D; Soria JC; Besse B; Farace F
    Ann Oncol; 2015 Jul; 26(7):1408-15. PubMed ID: 25846554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial.
    Michels S; Massutí B; Schildhaus HU; Franklin J; Sebastian M; Felip E; Grohé C; Rodriguez-Abreu D; Abdulla DSY; Bischoff H; Brandts C; Carcereny E; Corral J; Dingemans AC; Pereira E; Fassunke J; Fischer RN; Gardizi M; Heukamp L; Insa A; Kron A; Menon R; Persigehl T; Reck M; Riedel R; Rothschild SI; Scheel AH; Scheffler M; Schmalz P; Smit EF; Limburg M; Provencio M; Karachaliou N; Merkelbach-Bruse S; Hellmich M; Nogova L; Büttner R; Rosell R; Wolf J
    J Thorac Oncol; 2019 Jul; 14(7):1266-1276. PubMed ID: 30978502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001.
    Shaw AT; Riely GJ; Bang YJ; Kim DW; Camidge DR; Solomon BJ; Varella-Garcia M; Iafrate AJ; Shapiro GI; Usari T; Wang SC; Wilner KD; Clark JW; Ou SI
    Ann Oncol; 2019 Jul; 30(7):1121-1126. PubMed ID: 30980071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crizotinib inhibition of
    Bebb DG; Agulnik J; Albadine R; Banerji S; Bigras G; Butts C; Couture C; Cutz JC; Desmeules P; Ionescu DN; Leighl NB; Melosky B; Morzycki W; Rashid-Kolvear F; Lab C; Sekhon HS; Smith AC; Stockley TL; Torlakovic E; Xu Z; Tsao MS
    Curr Oncol; 2019 Aug; 26(4):e551-e557. PubMed ID: 31548824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.